EP1102786A4 - ANTISENSE OLIGONUCLEOTIDS WITH LOW ADENOSINE CONTENT, PREPARATION, KIT AND TREATMENT METHODS - Google Patents

ANTISENSE OLIGONUCLEOTIDS WITH LOW ADENOSINE CONTENT, PREPARATION, KIT AND TREATMENT METHODS

Info

Publication number
EP1102786A4
EP1102786A4 EP99939006A EP99939006A EP1102786A4 EP 1102786 A4 EP1102786 A4 EP 1102786A4 EP 99939006 A EP99939006 A EP 99939006A EP 99939006 A EP99939006 A EP 99939006A EP 1102786 A4 EP1102786 A4 EP 1102786A4
Authority
EP
European Patent Office
Prior art keywords
kit
preparation
treatment methods
adenosine content
low adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99939006A
Other languages
German (de)
French (fr)
Other versions
EP1102786A2 (en
Inventor
Jonathan W Nyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina University filed Critical East Carolina University
Publication of EP1102786A2 publication Critical patent/EP1102786A2/en
Publication of EP1102786A4 publication Critical patent/EP1102786A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP99939006A 1998-08-03 1999-08-03 ANTISENSE OLIGONUCLEOTIDS WITH LOW ADENOSINE CONTENT, PREPARATION, KIT AND TREATMENT METHODS Withdrawn EP1102786A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9521298P 1998-08-03 1998-08-03
US95212P 1998-08-03
PCT/US1999/017712 WO2000009525A2 (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments

Publications (2)

Publication Number Publication Date
EP1102786A2 EP1102786A2 (en) 2001-05-30
EP1102786A4 true EP1102786A4 (en) 2002-03-06

Family

ID=22250687

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99939006A Withdrawn EP1102786A4 (en) 1998-08-03 1999-08-03 ANTISENSE OLIGONUCLEOTIDS WITH LOW ADENOSINE CONTENT, PREPARATION, KIT AND TREATMENT METHODS

Country Status (6)

Country Link
EP (1) EP1102786A4 (en)
CN (1) CN1317009A (en)
AU (1) AU5337499A (en)
CA (1) CA2333901A1 (en)
HK (1) HK1042706A1 (en)
WO (1) WO2000009525A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
EP1165123A4 (en) * 1999-03-26 2002-09-11 Human Genome Sciences Inc 48 HUMAN SECRETED PROTEINS
EP1165783A4 (en) * 1999-03-26 2002-09-11 Human Genome Sciences Inc 47 HUMAN SECRETED PROTEINS
WO2000062736A2 (en) * 1999-04-06 2000-10-26 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
US6489151B1 (en) * 2000-03-27 2002-12-03 The Research Foundation Of State University Of New York Biologically active alternative form of the IKKα IκB kinase
DE10019252A1 (en) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydeoxyribonucleotides to inhibit ICAM-1 gene expression
DE10049549A1 (en) * 2000-10-06 2002-05-02 Markus Hecker Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7745420B2 (en) * 2001-07-06 2010-06-29 Topigen Pharmaceutique, Inc. Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US20060088835A1 (en) * 2002-04-05 2006-04-27 Pickard Benjamin S Schizophrenia associated genes
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
CN1322899C (en) * 2004-02-11 2007-06-27 中国科学院上海生命科学研究院 Anti-liver cancer gene drug composition, small molecule interfering RNA and screening method thereof
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
NZ554723A (en) 2004-10-29 2009-12-24 Topigen Pharmaceuticals Inc Antisense oligonucleotides against CCR3 chemokine receptor
MX2008002101A (en) 2005-08-12 2008-04-19 Schering Corp Mcp1 fusions.
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US10017762B2 (en) * 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
BR112013032223A2 (en) * 2011-06-15 2016-12-20 Grifols Therapeutics Inc isolated nucleic acid molecule and composition
CN102866153B (en) * 2012-09-29 2014-08-13 郑州安图生物工程股份有限公司 Prostatitis joint-detection kit
WO2014164805A1 (en) * 2013-03-11 2014-10-09 University Of North Carolina At Chapel Hill Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
JP2023548597A (en) * 2020-10-29 2023-11-17 エー． ガルシア－ブランコ，マリアーノ Soluble interleukin-7 receptor (sIL7R) modulation therapy to treat cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010820A1 (en) * 1991-11-26 1993-06-10 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
WO1993012756A2 (en) * 1991-12-17 1993-07-08 The Regents Of The University Of California Transfection of lung via aerosolized transgene delivery
WO1995035032A1 (en) * 1992-05-22 1995-12-28 The Scripps Research Institute SUPPRESSION OF NUCLEAR FACTOR-kB DEPENDENT PROCESSES USING OLIGONUCLEOTIDES
WO1996040162A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for lung diseases using antisense oligonucleotides
WO1998011211A2 (en) * 1996-09-10 1998-03-19 Hybridon, Inc. METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010820A1 (en) * 1991-11-26 1993-06-10 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
WO1993012756A2 (en) * 1991-12-17 1993-07-08 The Regents Of The University Of California Transfection of lung via aerosolized transgene delivery
WO1995035032A1 (en) * 1992-05-22 1995-12-28 The Scripps Research Institute SUPPRESSION OF NUCLEAR FACTOR-kB DEPENDENT PROCESSES USING OLIGONUCLEOTIDES
WO1996040162A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for lung diseases using antisense oligonucleotides
WO1998011211A2 (en) * 1996-09-10 1998-03-19 Hybridon, Inc. METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
LOAKES D ET AL: "5-NITROINDOLE AS AN UNIVERSAL BASE ANALOGUE", NUCLEIC ACIDS RESEARCH, vol. 22, no. 20, 1994, pages 4039 - 4043, XP000999195, ISSN: 0305-1048 *
METZGER W JAMES ET AL: "Oligonucleotide therapy of allergic asthma.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 104, no. 2 PART 1, August 1999 (1999-08-01), pages 260 - 266, XP001024505, ISSN: 0091-6749 *
NARAYANAN, R.: "The NK-kappaB transcription factor", STEIN, C.A. & KRIEG, A.M. 'APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY'. WILEY-LISS, NEW YORK, US; 1998; CHAPTER 12, pages 231 - 243, XP002185125 *
NICHOLS R ET AL: "A UNIVERSAL NUCLEOSIDE FOR USE AT AMBIGOUS SITES IN DNA PRIMERS", NATURE, vol. 369, no. 6480, 9 June 1994 (1994-06-09), pages 492 - 493, XP000560346, ISSN: 0028-0836 *
OHTSUKA E ET AL: "AN ALTERNATIVE APPROACH TO DEOXYOLIGONUCLEOTIDES AS HYBRIDIZATION PROBES BY INSERTION OF DEOXYINOSINE AT AMBIGUOUS CODON POSITIONS", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol. 260, no. 5, 10 March 1985 (1985-03-10), pages 2605 - 2608, XP002031938 *
RAHMAN M SAYEEDUR ET AL: "Nebularine (9-2'-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenine in vivo and in vitro.", MUTATION RESEARCH, vol. 377, no. 2, 1997, pages 263 - 268, XP001024479, ISSN: 0027-5107 *
See also references of WO0009525A3 *

Also Published As

Publication number Publication date
WO2000009525A3 (en) 2000-05-18
AU5337499A (en) 2000-03-06
WO2000009525A2 (en) 2000-02-24
CN1317009A (en) 2001-10-10
CA2333901A1 (en) 2000-02-24
EP1102786A2 (en) 2001-05-30
HK1042706A1 (en) 2002-08-23

Similar Documents

Publication Publication Date Title
EP1102786A4 (en) ANTISENSE OLIGONUCLEOTIDS WITH LOW ADENOSINE CONTENT, PREPARATION, KIT AND TREATMENT METHODS
EE200000653A (en) Benzothiophenes, benzofurans and indoles for use in the treatment of insulin resistance and hyperglycaemia
PT1322163E (en) SEED TREATMENT WITH PYRETHRIN / PYRETROID AND CLOTIANIDINE COMBINATIONS
NO980628D0 (en) Object with micro-organism-repellent coating, its preparation and use
EE200200414A (en) Dihydro-1,3,5-triazinamino derivatives and their use in therapy
DK0930828T3 (en) Cellulose preparation, its preparation and its use in food
PL344346A1 (en) Platinum complex, its preparation and therapeutic application
DK1073672T3 (en) Antipicornaviral compounds, their preparation and use
ATE348650T1 (en) REDUCTION IN HAIR GROWTH
IT1312195B1 (en) BULLET STABILIZED IN ROTATION AND PROCEDURE FOR ITS MANUFACTURE
NO991156L (en) Chocolate with reduced fat content
HUP9903249A3 (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
NO20000462D0 (en) 4-Oxo-3,5-dihydro-4H-pyridazino [4,5-b] indole-1-acetamide derivatives, their preparation and their use in therapy
HUP0201762A2 (en) Platinum complex, its preparation and therapeutic application
IL143082A0 (en) Benzofuran derivatives, their preparation and use
EE9800333A (en) Novel furanarylmethylidene derivatives, methods for their preparation and use in therapy
DK1061955T3 (en) Polynucleotide composition, method of preparation and use thereof
GB9820631D0 (en) Hair treatment composition, method and use
AR025731A1 (en) "DITIEPINO [6,5-B] BENZO-FUSIONATED PYRIDINS AND RELATED COMPOSITIONS AND METHODS"
ZA979442B (en) Nefazodone: Use in treating post traumatic stress disorder.
HUP0102409A3 (en) Pyrimidin-aminomethhyl-pyridine derivatives, their preparation and their use in the control of helicobacter bacteria
GB9800954D0 (en) Well treatment with micro-organisms
NO972821D0 (en) 1-C-perfluoroalkyl glycosides, their preparation and use
NO996156L (en) Substituted cycloheptans, their preparation and use
PL330791A1 (en) Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010205

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 6/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20020121

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DA4 Supplementary search report drawn up and despatched (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20020424

17Q First examination report despatched

Effective date: 20040223

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040706